
GRAL
Grail Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
36.580
Open
36.390
VWAP
35.35
Vol
992.36K
Mkt Cap
1.27B
Low
34.800
Amount
35.08M
EV/EBITDA(TTM)
--
Total Shares
35.97M
EV
591.32M
EV/OCF(TTM)
--
P/S(TTM)
8.81
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Show More
2 Analyst Rating

15.09% Upside
Wall Street analysts forecast GRAL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 40.50 USD with a low forecast of 38.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy

15.09% Upside
Current: 35.190

Low
38.00
Averages
40.50
High
43.00

15.09% Upside
Current: 35.190

Low
38.00
Averages
40.50
High
43.00
Morgan Stanley
Equal Weight
initiated
$20 -> $38
2025-06-26
Reason
Morgan Stanley
Price Target
$20 -> $38
2025-06-26
initiated
Equal Weight
Reason
Morgan Stanley assumed coverage of Grail with an Equal Weight rating and a price target of $38, up from $20. While the firm sees significant long-term potential for Grail's Galleri MCED test, there are also inherent risks associated with novel technologies from a regulatory and reimbursement standpoint, the analyst tells investors. The firm is also updating estimates for Q1 results, noting that its Q2 and 2025 revenue estimates move to $36M and $151M, from prior forecasts of $37M and $149M, respectively.
NINGI Research
NINGI Research
downgrade
$14.28
2025-06-09
Reason
NINGI Research
NINGI Research
Price Target
$14.28
2025-06-09
downgrade
Reason
Canaccord
Buy
maintain
$32 -> $43
2025-05-14
Reason
Canaccord
Price Target
$32 -> $43
2025-05-14
maintain
Buy
Reason
Canaccord Genuity
Kyle Mikson
Strong Buy
Initiates
$32
2025-04-21
Reason
Canaccord Genuity
Kyle Mikson
Price Target
$32
2025-04-21
Initiates
Strong Buy
Reason
Morgan Stanley
Tejas Savant
Hold
Maintains
$16 → $20
2025-03-18
Reason
Morgan Stanley
Tejas Savant
Price Target
$16 → $20
2025-03-18
Maintains
Hold
Reason
Morgan Stanley
Tejas Savant
Hold
Initiates
$16
2024-11-27
Reason
Morgan Stanley
Tejas Savant
Price Target
$16
2024-11-27
Initiates
Hold
Reason
Morgan Stanley initiated coverage of Grail with an Equal Weight rating and $16 price target. The company's Galleri multi-cancer early detection screening test has the potential to address a significant unmet need, the analyst tells investors in a research note. The firm says that while Grail's cash preservation efforts are encouraging, with Medicare reimbursement, the key catalyst to unlocking share value, essentially a 2027 dynamic, the stock's near-term risk/reward is balanced.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Grail Inc (GRAL.O) is -2.42, compared to its 5-year average forward P/E of -1.24. For a more detailed relative valuation and DCF analysis to assess Grail Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.24
Current PE
-2.42
Overvalued PE
-0.14
Undervalued PE
-2.35
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.62
Current EV/EBITDA
-1.87
Overvalued EV/EBITDA
0.38
Undervalued EV/EBITDA
-1.62
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued
5Y Average PS
4.56
Current PS
8.53
Overvalued PS
8.28
Undervalued PS
0.83
Financials
Annual
Quarterly
FY2025Q1
YoY :
+19.15%
31.84M
Total Revenue
FY2025Q1
YoY :
-32.44%
-153.64M
Operating Profit
FY2025Q1
YoY :
-51.48%
-106.21M
Net Income after Tax
FY2025Q1
YoY :
-62.42%
-3.10
EPS - Diluted
FY2025Q1
YoY :
-54.69%
-95.07M
Free Cash Flow
FY2025Q1
YoY :
-23.65%
-62.60
Gross Profit Margin - %
FY2025Q1
YoY :
-44.43%
-357.74
FCF Margin - %
FY2025Q1
YoY :
-59.28%
-333.61
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 3301.22% over the last month.
Sold
0-3
Months
23.9M
USD
6
3-6
Months
360.4K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
3.2M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
4
1.0M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
410.2K
Volume
1
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
12.5K
Volume
Months
6-9
1
1.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 3301.22% over the last month.
Sold
0-3
Months
23.9M
USD
6
3-6
Months
360.4K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
3.2M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
4
1.0M
USD
Months
GRAL News & Events
Events Timeline
2025-06-27 (ET)
2025-06-27
10:44:35
Supreme Court keeps element of Obamacare preventive care, Reuters reports


2025-06-18 (ET)
2025-06-18
09:03:52
Grail reports results from PATHFINDER 2 study

2025-05-13 (ET)
2025-05-13
16:03:39
Grail reports Q1 EPS ($3.10), consensus ($3.80)

Sign Up For More Events
Sign Up For More Events
News
5.0
06-20NewsfilterWith Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
4.5
06-18BenzingaWall Street Rises Ahead Of Fed, Payment Stocks Fall On Stablecoin Bill: What's Driving Markets Wednesday?
9.0
06-18NewsfilterGRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Sign Up For More News
People Also Watch

NAT
Nordic American Tankers Ltd
2.680
USD
-1.83%

KODK
Eastman Kodak Co
6.860
USD
+0.15%

RERE
ATRenew Inc
3.680
USD
+8.88%

LYTS
LSI Industries Inc
17.580
USD
+0.29%

ATEX
Anterix Inc
22.840
USD
+0.26%

LDI
loanDepot Inc
1.880
USD
+14.63%

SPFI
South Plains Financial Inc
41.000
USD
+0.99%

ACIC
American Coastal Insurance Corp
10.800
USD
-0.92%

FRPH
FRP Holdings Inc
26.940
USD
-1.03%

FARO
FARO Technologies Inc
43.990
USD
+0.48%
FAQ

What is Grail Inc (GRAL) stock price today?
The current price of GRAL is 35.19 USD — it has decreased -2.03 % in the last trading day.

What is Grail Inc (GRAL)'s business?

What is the price predicton of GRAL Stock?

What is Grail Inc (GRAL)'s revenue for the last quarter?

What is Grail Inc (GRAL)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Grail Inc (GRAL)'s fundamentals?

How many employees does Grail Inc (GRAL). have?
